Medtronic Buys Kanghui To Expand Orthopedic Market Presence In China
This article was originally published in PharmAsia News
Executive Summary
Medtronic buys the second largest orthopedic company in China on Sept. 27, gaining a strong local operation in the country and leaving the future of Medtronic’s 2007 ortho joint venture with Weigao uncertain.
You may also be interested in...
Kanghui: A New Strategic Opens The Door To Orthopedics In China
China Kanghui has emerged as one of the leaders in China’s orthopedics industry, building a business first on trauma and, more recently, spine. Now, with a pending move into reconstruction, the company is looking to other emerging markets, and eventually the US and Europe.
Medtronic Boosts Ortho Presence In China Under Weigao Joint Venture
Medtronic's joint venture with device maker Shandong Weigao gives Medtronic a 15% stake in the Chinese firm
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.